REmimazolam vs PrOpofol on Intraoperative hypotenSion in Major Noncardiac surgEry
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Intraoperative hypotension is common during major noncardiac surgery and is associated with
adverse postoperative outcomes. Propofol, the most commonly used intravenous anesthetic agent
worldwide, is associated with hypotension on induction and maintenance of general anesthesia.
Remimazolam is a newly developed short-acting benzodiazepine drug and has been approved for
use in procedural sedation and general anesthesia. It was associated with a lower incidence
of hypotension during procedural sedation in previous studies. The aim of this study is to
tested the primary hypothesis that total intravenous anesthesia with remimazolam reduces the
duration and severity of hypotension during major noncardiac surgery compared with total
intravenous anesthesia with propofol.